Ellen M. Zane

October 17, 2026

Synchrony Financial Prepares for Q3 Earnings Amid Mixed Analyst Views. Synchrony Financial is approaching its third-quarter earnings report, with analysts expecting lower results compared to previous periods. While some market participants are watching for higher purchase volumes to support performance, recent stock price movements have been volatile. The company's current valuation remains low relative to its peer group, and its preferred shares have seen increased interest due to yield.

October 10, 2026

Haemonetics Gets Price Target Hikes Amid Recent Stock Jump. Barrington Research and Mizuho both raised their price targets for Haemonetics to $140, maintaining Outperform ratings. This follows a recent 17.5% jump in the stock, which is now trading near its 52-week high. While some analysts note the current price may not be an ideal entry point, the firm's outlook has improved due to CSL Plasma developments.

October 17, 2026

Boston Scientific (BSX) Faces Catheter Recall Amid Valuation Debate. Boston Scientific announced a recall of 262,686 catheters because of a life‑threatening tip failure risk. The recall adds pressure as analysts note the company needs clear evidence of its turnaround to justify a better valuation. Truist Securities kept its rating but cut its price target to $51, reflecting a more cautious view. The stock has still moved higher than the broader market, indicating mixed investor reactions.

October 15, 2026

AZTA Featured in Volatile Stock List. Azenta Inc. was included in a recent article discussing volatile stocks with promising prospects. The stock is currently trading within its 52-week range, with analysts maintaining an average price target of $37.00. This mention highlights the company's status as a high-beta asset in the current market environment.